Tesamorelin + Ipamorelin calculator
A pairing of the approved GHRH analog tesamorelin with the secretagogue ipamorelin. Tesamorelin alone is approved; the combination is not studied.
Also known as: Tesa/Ipa blend, GHRH + secretagogue blend
FDA status — not an approved drug Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy. Ipamorelin is not approved, and no combination of the two is approved or studied.
Schedule Tesamorelin + Ipamorelin → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Tesamorelin + Ipamorelin is
Tesamorelin with ipamorelin is a blend pairing the approved GHRH analog tesamorelin with the unapproved secretagogue ipamorelin. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy, but the combination has no clinical evidence and is not a standardized or approved product.
Research depth: 2/5 Strong data for tesamorelin alone, but no trials of the combination. Human trials: None for the combination. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Tesamorelin + Ipamorelin works
The two act on complementary pituitary receptors: tesamorelin activates GHRH receptors while ipamorelin activates ghrelin/GHSR receptors, both promoting growth-hormone release. Combining them is intended to produce a stronger pulse, but the combination has not been studied for safety or efficacy.
Tesamorelin + Ipamorelin side effects
Commonly reported
- Injection-site reactions
- Flushing and headache
- Water retention and joint aches
- No studies of the combination
Serious — seek medical care
- Unstudied combination — interactions unknown
- Sustained GH elevation raises insulin-resistance and fluid-retention concern
- Ipamorelin is unapproved and unstandardized in blends
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 2000 mcg dose is then 0.4 mL — about 40 units on a 100-unit insulin syringe, giving roughly 5 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Tesamorelin + Ipamorelin dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Tesamorelin + Ipamorelin run from 1000 mcg to 2000 mcg. No established dosing exists for the combination. Figures reflect the tesamorelin component's labeled amount. Ipamorelin is unapproved and unstandardized in blends.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Tesamorelin + Ipamorelin at all are decisions for a licensed clinician who knows your history.
Common questions
Is there an approved tesamorelin-ipamorelin combination?
No. Tesamorelin is approved alone as Egrifta for a specific indication. Ipamorelin is unapproved, and no trial has studied the two together. Blends are unregulated.
Why combine them?
Both act on growth-hormone release — tesamorelin on GHRH receptors, ipamorelin on ghrelin receptors — so the pairing is intended to be complementary. The combination itself has no clinical evidence.